Descripción de la empresa
Elicio Therapeutics, Inc. operates as a clinical-stage biotechnology entity dedicated to the development of immunotherapies designed for the treatment of cancer. The company functions within the healthcare sector and specifically the biotechnology industry, a field characterized by high capital expenditure requirements and significant regulatory hurdles before products reach the market. With a market capitalization of $185.62M and an employee count of 33, the firm maintains a lean operational structure typical of early-to-mid-stage biotech ventures. The reported revenue figure is N/A, indicating that the company has not yet generated significant commercial sales from its pipeline products. This valuation and lack of substantial revenue reflect the early phase of the company's commercialization journey, where value is derived primarily from the potential of its lead product candidate, ELI-002, rather than current cash flow generation. The small workforce relative to the market cap suggests a high leverage of intellectual property and research capabilities per employee, a common trait in biotechnology firms awaiting clinical trial milestones.
Salud financiera
The financial profile of Elicio Therapeutics, Inc. reveals a net income of $-39,571,000 and an EBITDA of $-37,510,000, while the revenue figure remains N/A. The substantial gap between the reported revenue (which is effectively zero in commercial terms) and the significant net loss highlights an operational cost structure dominated by research and development expenses rather than cost of goods sold. The company reports a free cash flow of $-21,666,376, which indicates a continuous burn rate that consumes available liquidity to fund ongoing clinical trials and operational overhead. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, a status that signifies the company has not yet crossed the threshold into profitability or has not reported commercial revenue sufficient to calculate traditional margins. On the balance sheet, the company holds $18.56M in cash against $14.51M in debt, resulting in a debt-to-equity ratio of 887.04, which suggests a highly leveraged position relative to its equity base but maintains a conservative short-term liquidity stance supported by a current ratio of 2.38. The return on equity is N/A due to the lack of profitability, while the return on assets stands at -87.2%, revealing that the asset base is currently generating negative returns on capital employed.
Evaluación de valoración
The valuation metrics for Elicio Therapeutics, Inc. present a trailing P/E ratio of N/A and a forward P/E of -7.21. The absence of a trailing P/E confirms the lack of positive earnings over the trailing twelve months, while the negative forward P/E implies that analysts or market models project continued losses or that earnings are insufficient to support a traditional multiple. The price-to-book ratio is elevated at 109.67, indicating that the market values the company at a significant premium over its book value, likely due to the intangible value of its pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio are N/A due to negligible sales, while the EV/EBITDA is -4.84, further emphasizing the speculative nature of the stock price relative to cash flows. The stock has traded between a 52-week low of $4.60 and a 52-week high of $14.93, placing the current market price within a wide volatility band that reflects the binary risks associated with clinical-stage assets. The beta of 1.88 indicates that the stock exhibits high price volatility, moving with nearly double the intensity of the broader market, which aligns with the high-risk profile of biotechnology equities awaiting clinical trial data.
Growth & Income
The revenue growth year-over-year is N/A, and the earnings growth year-over-year is also N/A, as the company has not yet established a consistent history of commercial sales or profitable earnings. In the absence of positive earnings, the concept of dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Instead of paying dividends, the company retains its limited cash reserves and negative earnings to reinvest entirely into the advancement of its immunotherapy pipeline and to sustain its R&D operations. The overall growth and income profile for Elicio Therapeutics, Inc. is currently defined by capital appreciation potential rather than income generation, relying on the successful progression of its lead product through Phase II clinical trials to eventually unlock commercial revenue streams.